Biora Therapeutics Inc (BIOR)vsRegeneron Pharmaceuticals Inc (REGN)
BIOR
Biora Therapeutics Inc
$0.22
0.00%
HEALTHCARE · Cap: $994,990
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1667679% more annual revenue ($14.34B vs $860,000). REGN leads profitability with a 31.4% profit margin vs 0.0%. BIOR trades at a lower P/E of 0.6x. REGN earns a higher WallStSmart Score of 58/100 (C).
BIOR
Hold38
out of 100
Grade: F
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+91.0%
Fair Value
$2.45
Current Price
$0.22
$2.23 discount
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Revenue surging 158.0% year-over-year
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : BIOR
The strongest argument for BIOR centers on P/E Ratio, Revenue Growth. Revenue growth of 158.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : BIOR
The primary concerns for BIOR are EPS Growth, Market Cap, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
BIOR profiles as a hypergrowth stock while REGN is a value play — different risk/reward profiles.
BIOR carries more volatility with a beta of 1.28 — expect wider price swings.
BIOR is growing revenue faster at 158.0% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 38/100), backed by strong 31.4% margins. BIOR offers better value entry with a 91.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biora Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapeutic products. The company is headquartered in San Diego, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?